JUNTING YIN

Partner Fangda Partners

+86 10 5769 5600 Junting.Yin@fangdalaw.com



PRACTICE AREAS

MR. YIN'S PRACTICE FOCUSES ON PATENT INVALIDITY AND RELATED ADMINISTRATIVE LITIGATION PROCEEDINGS, PATENT LITIGATION, AND TRADE SECRET MISAPPROPRIATION.

REPRESENTATIVE MATTERS AND CASES

- Represented Medivation in an administrative litigation proceeding concerning pharmaceutical patents
- Represented Care Strategic in a series of patent invalidity proceedings against Shenzhen JUDCare concerning medical devices
- Advised University of California Board of Regents on administrative litigation proceedings concerning pharmaceutical patents
- Represented Intel in a patent infringement lawsuit filed by VLSI Technology and in patent invalidity and administrative litigation proceedings concerning a patent for processor technology
- Represented Apple in a patent infringement lawsuit filed by France Brevets concerning a patent for NFC technology
- Represented Apple in several patent infringement lawsuits filed by Flexiworld Technologies concerning patents for network communication technology
- Represented WhatsApp in a patent infringement lawsuit filed by Wireless Wonders and in invalidity proceedings concerning a patent for network communication technology
- Represented Arcam in a series of patent invalidity proceedings
- Represented a leading Chinese chemical company in a patent invalidity proceeding

- Represented a leading Chinese mechanical manufacturer in trade secret misappropriation litigation and patent invalidity proceedings
- Advised Illumina, Novartis, etc. on patent infringement and patent stability risks and on other legal issues

OTHER INFORMATION

Education

- Shandong Academy of Medical Sciences, Master of Medicine
- Shandong University, Bachelor of Medicine

Professional Qualification

- Admitted to practice in PRC
- Admitted to practice before SIPO

Professional Background

Before joining Fangda, Mr. Yin served for over 10 years as a patent examiner at CNIPA's Pharmaceutical and Biological Examination Department for substantive examination and at its Patent Reexamination Board for reexamination and invalidity. He examined hundreds of patent reexamination and invalidation cases for chemical, pharmaceutical and mechanical invention patents and design patents, including invalidity cases involving Lenalidomide, Imatinib, Erlotinib, Chidamide, Sofosbuvir, Tenofovir alafenamide, and Velpatasvir.